3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
2
Completed
2
Unknown
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Lymphoid
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Neoplasm Metastasis
8
Lung Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Neoplasms
6
Ovarian Neoplasms
5
Melanoma
5
Carcinoma, Renal Cell
5
Skin Neoplasms
4
Fallopian Tube Neoplasms
4
Carcinoma
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Mouth Neoplasms
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Laryngeal Neoplasms
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Interventions
pembrolizumab
20
Gemcitabine
18
Cisplatin
14
Magnetic Resonance Spectroscopy
13
enfortumab vedotin
12
Specimen Handling
10
Cystectomy
10
Docetaxel
8
Mitomycin
7
Standard of Care
6
Cystoscopy
6
Transurethral Resection of Bladder
5
Radiotherapy
5
Carboplatin
5
durvalumab
4
Practice Guidelines as Topic
4
Nivolumab
4
Radiation
3
Multiparametric Magnetic Resonance Imaging
3
Mitozytrex
3
Fluorouracil
3
tislelizumab
2
dehydroftorafur
2
cemiplimab
2
avelumab
2
alvimopan
2
Therapeutics
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Radiosurgery
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Urinary Bladder Neoplasms
×
cemiplimab
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled
NCT06571708
2025-09-02
NeoSTOP-IT
Columbia University
Phase 2
Recruiting
36 enrolled